Roderick Greef - BioLife Solutions Interim CFO, Interim Secretary
| BLFS Stock | USD 24.99 0.07 0.28% |
CFO
Mr. Roderick de Greef is the Chief Financial Officer, Secretary of the Company. He was appointed interim Chief Financial Officer and interim Secretary in March 2016. Previously, Mr. de Greef served as a director of the Company from June 2000 through November 2013, and provided the Company with strategic and financial consulting services from July 2007 through August 2011. Mr. de Greef has served Pareteum Corporationrationration., a mobile communications company, as a director, chair of the Audit Committee and member of the Nominating and Corporationrationrate Governance Committee and Compensation Committee from September 2015 to September 2017, and also from January 2008 to October 2011. From November 2013 to October 2014, Mr. de Greef served as the president and sole director of Cambridge Cardiac Technologies, Inc. a privately held successor to Cambridge Heart, Inc. From November 2008 to October 2013, Mr. de Greef was the chairman of the board of Cambridge Heart, Inc., a manufacturer of noninvasive diagnostic cardiology products. From November 2003 to May 2013, Mr. de Greef served as a director, member of the Audit Committee and chairman of the Compensation Committee of Endologix, Inc. From 2001 to 2006, Mr. de Greef served as Executive Vice President and Chief Financial Officer of NASDAQ listed Cardiac Science, Inc., which in 2004 was ranked as the 4th fastest growing technology company in North America on Deloitte Touches Fast 500 listing. Mr. de Greef received his MBA degree from the University of Oregon, and a B.A in Economics and International Relations from San Francisco State University. Mr. de Greef has extensive experience in corporate finance and the business world in general as well as serving as an officer and director of public companies. since 2017.
| Age | 65 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Address | 3303 Monte Villa Parkway, Bothell, WA, United States, 98021 |
| Phone | 425 402 1400 |
| Web | https://www.biolifesolutions.com |
BioLife Solutions Management Efficiency
The company has return on total asset (ROA) of (0.011) % which means that it has lost $0.011 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0332) %, meaning that it created substantial loss on money invested by shareholders. BioLife Solutions' management efficiency ratios could be used to measure how well BioLife Solutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.12 in 2025. Return On Capital Employed is likely to drop to -0.02 in 2025. At this time, BioLife Solutions' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 263.3 M in 2025, whereas Return On Tangible Assets are likely to drop (0.12) in 2025.Similar Executives
| Found 7 records | CFO Age | ||
| Timothy Stonesifer | Alcon AG | 58 | |
| John Ek | Akoya Biosciences | 48 | |
| Brett Sandercock | ResMed Inc | 58 | |
| John CPA | Akoya Biosciences | 48 | |
| Vanessa Kanu | AptarGroup | 47 | |
| MBA BS | Teleflex Incorporated | 63 | |
| James CPA | Haemonetics | 54 | |
Management Performance
| Return On Equity | -0.0332 | ||||
| Return On Asset | -0.011 |
BioLife Solutions Leadership Team
Elected by the shareholders, the BioLife Solutions' board of directors comprises two types of representatives: BioLife Solutions inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioLife. The board's role is to monitor BioLife Solutions' management team and ensure that shareholders' interests are well served. BioLife Solutions' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioLife Solutions' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Aby Mathew, Chairman of Scientific Advisory Board, CTO and Sr. VP | ||
| Sarah JD, Chief Officer | ||
| Troy Wichterman, Chief Officer | ||
| Geraint Phillips, Senior Operations | ||
| Todd Berard, Vice President of Marketing | ||
| Karen Foster, Vice President - Operations | ||
| Troy CPA, Chief Officer | ||
| Sean Werner, Chief Officer | ||
| Marcus Schulz, Chief Officer | ||
| Michael Rice, CEO and President and Director | ||
| Roderick Greef, Interim CFO, Interim Secretary |
BioLife Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioLife Solutions a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0332 | ||||
| Return On Asset | -0.011 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | (0.40) % | ||||
| Current Valuation | 1.1 B | ||||
| Shares Outstanding | 46.91 M | ||||
| Shares Owned By Insiders | 1.84 % | ||||
| Shares Owned By Institutions | 98.16 % | ||||
| Number Of Shares Shorted | 3.37 M | ||||
| Price To Earning | 173.59 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BioLife Stock Analysis
When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.